MRNA three-lens brief
Evidence-based stock research on MRNA. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Moved -4.54% yesterday. · Underperforming SPY by 13.2pp over 30 days.
- Moved -4.54% yesterday.
- Underperforming SPY by 13.2pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $43.37 — 15% below current (19 analysts).
- Negative free cash flow last quarterly (-$497.75M).
MRNA closed at $50.85 (-4.54%) as of 2026-05-13. Market cap: $20.18B. Concerns: moved -4.54% yesterday.; underperforming SPY by 13.2pp over 30 days.. Last quarter: Revenue $389.00M, net income -$1.34B, free cash flow -$497.75M.
Why three lenses on MRNA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine MRNAacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/MRNA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath MRNA brief"></iframe>